FDA’s Opioid Crisis Response: More Pressure For Treatment Drugs
Executive Summary
Sharp increases in deaths from illicit drugs (heroin and synthetic opioids) could change FDA's priorities; rather than working with drug sponsors on more tamper-deterrent formulations of pain therapies, the agency may need to devote more attention to overdose treatments like naloxone.
You may also be interested in...
Naloxone Efficacy Standard Changes Could Impact Amphastar's Pending NDA
FDA is reviewing Amphastar’s application for a new intranasal formulation at the same time it is reconsidering minimum pharmacokinetic standards for the opioid overdose reversal agent.
Higher Naloxone Doses Narrowly Favored By FDA Panel
Divided advisory committee concludes the current naloxone approval standard is inadequate due in part to increase in overdoses from powerful synthetic opioids, but doesn't offer FDA a clear alternative.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.